SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-021359
Filing Date
2023-05-11
Accepted
2023-05-11 17:00:23
Documents
13
Period of Report
2023-05-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20230509.htm   iXBRL 8-K 66975
2 EX-3.1 vktx-ex3_1.htm EX-3.1 238401
  Complete submission text file 0000950170-23-021359.txt   472849

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vktx-20230509_pre.xml EX-101.PRE 11567
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vktx-20230509.xsd EX-101.SCH 2492
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vktx-20230509_lab.xml EX-101.LAB 18302
7 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20230509_htm.xml XML 4900
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 23911985
SIC: 2834 Pharmaceutical Preparations